Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-11-137594
Filing Date
2011-05-12
Accepted
2011-05-12 16:10:34
Documents
7
Period of Report
2011-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d10q.htm 10-Q 860195
2 STOCK PURCHASE AGREEMENT - CALANDO PHARMACEUTICALS, INC. dex101.htm EX-10.1 42648
3 STOCK PURCHASE AGREEMENT - ABLARIS THERAPEUTICS, INC. dex102.htm EX-10.2 52487
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 dex311.htm EX-31.1 6884
5 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 dex312.htm EX-31.2 6865
6 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 dex321.htm EX-32.1 3238
7 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 dex322.htm EX-32.2 3102
  Complete submission text file 0001193125-11-137594.txt   976654
Mailing Address 201 SOUTH LAKE AVENUE SUITE 703 PASADENA CA 91101
Business Address 201 SOUTH LAKE AVENUE SUITE 703 PASADENA CA 91101 626-304-3400
ARROWHEAD RESEARCH CORP (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 000-21898 | Film No.: 11835928
SIC: 8731 Services-Commercial Physical & Biological Research